BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dini V, Romanelli M, Bertone M, Talarico S, Bombardieri S, Barachini P. Improvement of Idiopathic Pyoderma Gangrenosum During Treatment With Anti-Tumor Necrosis Factor Alfa Monoclonal Antibody. The International Journal of Lower Extremity Wounds 2007;6:108-13. [DOI: 10.1177/1534734607300912] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Cañas CA, Durán CE, Bravo JC, Castaño DE, Tobón GJ. Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation. Rheumatol Int 2010;30:1253-7. [DOI: 10.1007/s00296-010-1418-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
2 Cecchi R, Pavesi M, Bartoli L, Brunetti L. Successful Treatment of Localized Pyoderma Gangrenosum with Topical Pimecrolimus. J Cutan Med Surg 2012;16:295-7. [DOI: 10.1177/120347541201600503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Andrisani G, Guidi L, Papa A, Potenza A, Cervelli D, Armuzzi A. A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. Journal of Crohn's and Colitis 2013;7:421-6. [DOI: 10.1016/j.crohns.2012.07.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Adışen E, Erduran F, Gürer MA. Pyoderma Gangrenosum: A Report of 27 Patients. Int J Low Extrem Wounds 2016;15:148-54. [PMID: 27009790 DOI: 10.1177/1534734616639172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Calonje E, Brenn T, Lazar A. Neutrophilic and eosinophilic dermatoses. McKee's Pathology of the Skin. Elsevier; 2012. pp. 631-57. [DOI: 10.1016/b978-1-4160-5649-2.00015-9] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J 2019;16:511-21. [PMID: 30604927 DOI: 10.1111/iwj.13067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
7 Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V. PG-TIME: A practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 2020;33:e13412. [PMID: 32291879 DOI: 10.1111/dth.13412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Janowska A, Dini V, Oranges T, Iannone M, Loggini B, Romanelli M. Atypical Ulcers: Diagnosis and Management. Clin Interv Aging 2019;14:2137-43. [PMID: 31849457 DOI: 10.2147/CIA.S231896] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Salvo P, Dini V, Kirchhain A, Janowska A, Oranges T, Chiricozzi A, Lomonaco T, Di Francesco F, Romanelli M. Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review. Sensors (Basel) 2017;17:E2952. [PMID: 29257113 DOI: 10.3390/s17122952] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
10 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
11 Pérez-De Pedro I, Gómez-Moyano E, López-Carmona D, Muñoz-Roca NL, De Ramón-Garrido E, Camps-García MT. [Utility of infliximab in gangrenous pyoderma not associated with inflammatory bowel disease]. Rev Clin Esp 2010;210:367-9. [PMID: 20466360 DOI: 10.1016/j.rce.2009.11.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Romanelli M, Dini V, Vowden P, Agren MS. Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence. Clin Interv Aging 2008;3:263-72. [PMID: 18686749 DOI: 10.2147/cia.s1846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
13 Wollina U, Haroske G. Pyoderma gangraenosum. Current Opinion in Rheumatology 2011;23:50-6. [DOI: 10.1097/bor.0b013e328341152f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
14 Dupuis E, Zarbafian M, Asgarpour J, Parsons L, Mydlarski PR. Plasmablasticlike lymphoma arising within chronic pyoderma gangrenosum. JAAD Case Rep 2017;3:200-1. [PMID: 28443308 DOI: 10.1016/j.jdcr.2017.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]